NCT04158102已完成1 期
A Phase 1, Open Label Study to Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- plasma concentration
研究概览
简要总结
This is a single-center, open-label, single-dose study to evaluate the safety, pharmacokinetics in healthy subjects
详细描述
This is a phase I, open-label, single-dose in healthy subjects conducted at single center.The objectives are to evaluate the metabolic and safety profile of EXPAREL®. Each volunteer will receive one dose of the investigational drug via subcutaneous injection at multiple points during the study period. Study duration is around 54 days, including screening, confinement, ambulatory visit and a phone follow up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Chinese male or female subjects, and his/her biological parents and grandparents are of Chinese ethnicity.
- •Aged ≥18 and ≤55 years of age at screening, inclusive.
- •Willing and able to give written informed consent and comply with the study visit schedule, study procedures and restrictions.
- •Generally, in good health with no clinically significant abnormalities as determined by medical history, physical examination, 12-lead ECG and clinical laboratory tests.
- •Have a body mass index (BMI) between 19.0 and 24.0 kg/m2, inclusive, and a body weight ≥50 kg at screening visit and baseline visit (Day -1).
排除标准
- •Female subjects who are pregnant (positive pregnancy result at screening and on Day -1), or lactating.
- •Female subjects of child bearing potential and sexually active don't agree to use medically acceptable contraceptive (e.g. insertable, injectable, transdermal, hormonal contraceptive) from the date of consent given until 30 days after administration of study drug. Menopausal woman don't have her menopausal status confirmed by follicle-stimulating hormone test at screening.
- •Male subjects who are sexually active don't agree to use condom plus spermicide since the dosing day till 90 days after administration of study drug.
- •Male subjects don't agree not to donate sperm since the dosing day till 90 days after administration of study drug.
- •Presence of any concomitant clinically significant diseases, that would interfere with the study based on the investigator's discretion.
- •History of hypersensitivity or idiopathic reaction to amide-type local anesthetics.
- •Has a positive urine drug screen result for drugs of abuse or a positive blood alcohol test at the Screening Visit or baseline visit (Day-1).
- •Has an abnormal (clinically significant) ECG at the screening visit. Entry of any subject with an abnormal (but not clinically significant) ECG must be approved and documented by signature of the Investigator or medically qualified subinvestigator.
- •Has a supine BP outside the ranges of 90 to 140 mmHg for systolic BP and 50 to 90 mmHg, inclusive, for diastolic BP, or resting pulse rate outside the range of 40 to 100 beats per minute. If any of the values are out of range, the assessment may be repeated twice for eligibility determination at the screening visit or baseline visit (Day-1).
- •Positive HIV test result at screening.
- •Positive testing for HBs Antigen and/or a positive Hepatitis C antibody test result at screening.
- •Has an abnormal laboratory values outside the reference range that are of clinical significance which may suggest of an underlying disease such as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values, greater than 1.5 times the upper limit of normal.
- •Intake prescription or over the counter products (vitamins, dietary supplements, herbal preparations, etc.) within 14 days or less than 5 half-lives (whichever is longer) prior to screening visit.
- •Blood loss or donation more than 450ml within 3 months prior to dosing.
- •Previous participation in an EXPAREL® study.
- •Administration of an investigational drug within 30 days or 5 elimination half-lives of the investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
研究组 & 干预措施
20 mg single dose cohort
Experimental
Subjects would receive a 20 mg single dose of EXPAREL®
干预措施: Bupivacaine liposome injectable suspension (Drug)
结局指标
主要结局
plasma concentration
时间窗: up to 14 days
Maximum observed plasma concentration (Cmax)
Area under the plasma concentration-versus-time curve
时间窗: up to 14 days
Area under the plasma concentration-versus-time curve from time 0 extrapolated to infinity after drug administration (AUC0-∞)
次要结局
- Incidence of adverse events（AEs）which are related to exparel injection(up to 21 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic FunctionHepatic ImpairmentNCT01631097AVEO Pharmaceuticals, Inc.44
已完成
1 期
Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD3043HealthyNCT00918515AstraZeneca53
已完成
1 期
Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female SubjectsPhase 1NCT04327089Calliditas Therapeutics AB64
已完成
1 期
Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White ParticipantsHealthy ParticipantsNCT05033431AstraZeneca48
撤回
1 期
Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043SafetyTolerabilityPharmacokineticsSedationNCT01086813AstraZeneca